Healthcare Industry News: pacing leads
News Release - February 14, 2008
Spectranetics Appoints Thomas Rasmussen Vice President of Clinical AffairsCOLORADO SPRINGS, Colo.--(HSMN NewsFeed)--Spectranetics Corporation (Nasdaq: SPNC ) today announced it has appointed Thomas M. Rasmussen as Vice President of Clinical Affairs.
Mr. Rasmussen has nearly two decades experience managing clinical programs for cardiovascular medical device companies. Most recently he was director of clinical research for the Cardiac Rhythm Management (CRM) division of Boston Scientific Corporation, and held the same position at Guidant Corporation prior to Boston Scientific’s acquisition of Guidant. In those positions he was responsible for helping bring to market multiple CRM products, including bradycardia and tachycardia pacing leads and generators, heart failure pacing devices, programmers and software, and new therapy features. He previously held clinical program management positions at Sulzer Intermedics, Inc., and G.V. Medical, Inc. Mr. Rasmussen holds a bachelors degree in biology from the University of St. Thomas in St. Paul, Minnesota, and has performed graduate work at the University of Minnesota’s Graduate School of Pharmacology in Minneapolis.
“We are very pleased to have someone of the caliber of Tom Rasmussen join our management team,” said John G. Schulte, Spectranetics’ President and Chief Executive Officer. “He has planned and directed the development of several important Class III medical devices, and has successfully managed complex trial programs and large business and scientific teams. His combination of strategic thinking and management skills will play an important role in our development and commercialization of new products.”
Founded in 1984, Spectranetics manufactures and sells the only excimer laser approved in the United States, Europe and Japan for use in minimally invasive cardiovascular procedures. This technology treats complex cardiovascular conditions by photo-ablating multiple lesion types into tiny particles that are easily absorbed into the blood stream. The Company’s disposable catheters use high-energy “cool” ultraviolet light to vaporize arterial blockages in the legs and heart, as well as scar tissue encapsulating pacing and defibrillation leads. For more information, visit www.spectranetics.com.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.